Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
